文献速递老年精神心境障碍

去甲肾上腺素转运体基因变异与老年抑郁症文拉法辛治疗缓解的关系

Norepinephrine Transporter Gene Variants and Remission From Depression With Venlafaxine Treatment in Older Adults.
PubMed 文献 · Am J Psychiatry · 2017-01-10

本研究纳入350名60岁及以上重性抑郁障碍患者,接受开放标签文拉法辛治疗至多300 mg/天约12周,检测22个基因多态性。经多重比较校正后,NET基因rs2242446位点与缓解显著相关(OR=1.66,95%CI=1.13-2.42),C/C基因型缓解率更高且缓解时间更短。

要点

  • NET rs2242446 C/C基因型老年抑郁患者文拉法辛缓解率73.1%,高于C/T的51.8%和T/T的47.3%。
  • rs2242446与文拉法辛治疗缓解显著相关,校正后OR=1.66(95%CI=1.13-2.42)。
  • C/C基因型患者MADRS评分自基线至治疗结束(至第12周)的百分比变化更大。

核心结论

  • NET rs2242446/T-182C可能作为预测老年重性抑郁患者文拉法辛治疗缓解的生物标志物。

研究设计与样本

  • 三中心临床试验,纳入350名60岁及以上DSM-IV重性抑郁障碍患者,MADRS评分至少15分。
  • 参与者接受开放标签文拉法辛治疗,至多300 mg/天,约12周。
  • 对8个基因的22个多态性进行基因分型,检验其与文拉法辛缓解(MADRS≤10分)及MADRS评分变化的关联。

主要发现

  • 经多重比较校正后,NET变异rs2242446(T-182C)与缓解显著相关(OR=1.66,95%CI=1.13-2.42)。
  • rs2242446 C/C基因型个体缓解率为73.1%,高于C/T基因型的51.8%和T/T基因型的47.3%。
  • C/C基因型个体较C/T或T/T基因型个体缓解时间更短,且MADRS评分自基线至治疗结束(至第12周)的百分比变化更大。

关键数值与推荐

  • 缓解定义为MADRS评分≤10分。
  • 文拉法辛剂量至多300 mg/天,治疗约12周。

临床怎么用

  • 对于老年重性抑郁患者,NET rs2242446/T-182C基因型可能有助于预测文拉法辛治疗缓解可能性,辅助优化抗抑郁治疗决策。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The primary objective of this study was to investigate five putatively functional variants of the norepinephrine transporter (SLC6A2, NET) and serotonin transporter (SLC6A4, SERT) genes and remission in depressed older adults treated with venlafaxine. A secondary objective was to analyze 17 other variants in serotonergic system genes (HTR1A, HTR2A, HTR1B, HTR2C, TPH1, TPH2) potentially involved in the mechanism of action of venlafaxine. METHOD: The sample included 350 adults age 60 or older with DSM-IV-defined major depressive disorder and a score of at least 15 on the Montgomery-Åsberg Depression Rating Scale (MADRS). Participants received protocolized treatment with open-label venlafaxine, up to 300 mg/day for approximately 12 weeks, as part of a three-site clinical trial. Each individual was genotyped for 22 polymorphisms in eight genes, which were tested for association with venlafaxine remission (a MADRS score ≤10) and changes in MADRS score during treatment. RESULTS: After adjusting for multiple comparisons, NET variant rs2242446 (T-182C) was significantly associated with remission (odds ratio=1.66, 95% CI=1.13, 2.42). Individuals with the rs2242446 C/C genotype were more likely to remit (73.1%) than those with either the C/T (51.8%) or the T/T genotype (47.3%). Individuals with the C/C genotype also had a shorter time to remission than those with the C/T or T/T genotypes and had a greater percentage change in MADRS score from baseline to end of treatment (up to week 12). CONCLUSIONS: NET rs2242446/T-182C may serve as a biomarker to predict the likelihood of remission with venlafaxine in older adults with major depression. These findings may help to optimize antidepressant outcomes in older adults.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Marshe VS, Maciukiewicz M, Rej S, et al. Norepinephrine Transporter Gene Variants and Remission From Depression With Venlafaxine Treatment in Older Adults. Am J Psychiatry. 2017. PMID: 28068779. doi:10.1176/appi.ajp.2016.16050617

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。